Impact of an Intensive Monitoring Strategy in Symptomatic Patients With Suspected Arrhythmia

NCT ID: NCT03001765

Last Updated: 2019-10-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis:

Patients that were previously discharged from the emergency department with a subsequent non-diagnostic 30 day external patch monitor for suspected arrhythmia will benefit from early Reveal LINQ™ Insertable Cardiac Monitoring System placement.

Primary Study Objectives:

To evaluate the outcome of an intensive monitoring strategy (patients with a negative 30 day SEEQ™ Mobile Cardiac Telemetry (MCT) System result are purposed over for a Reveal LINQ™ Insertable Cardiac Monitoring System) in patients with suspected but no previously documented arrhythmias that result in a clinically actionable event.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients will be enrolled after presentation to the Emergency Department of St. Elizabeth Healthcare with symptoms suggestive of cardiac arrhythmia and prior to leaving the emergency department. Patients will be exited from the study and considered complete at the identification of a cardiac arrhythmia as defined in the protocol (endpoint), or 12 months from enrollment date, whichever occurs first.

Protocol defined endpoints

1. Planned insertion of a permanent pacemaker, implantable cardiac defibrillator or chronic resynchronization device.
2. Planned cardiac ablation procedure.
3. Initiation of medical therapy for the purpose of treating dysrhythmia.
4. Diagnosis of arrhythmia not requiring medical or invasive arrhythmia management.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Suspected Arrhythmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac

Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.

Group Type OTHER

Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System".

Intervention Type OTHER

Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System".

Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>18 years of age
* Patient present to the ED with symptoms suggestive of cardiac arrhythmia
* English is the patient's primary language
* Willing and able to provide consent for participation in the study
* Patient is willing and able to comply with the protocol including the required follow-up

Exclusion Criteria

* Refusal to participate
* Age \< 18 years of age
* Unable to provide consent
* Current implanted loop recorder, or loop recorder explanted within the past 12 months.
* Current implant of cardiac implantable electronic device, such as permanent pacemaker (PPM), implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) device.
* Life expectancy \< 12 months
* History of prior cardiac ablation or electrophysiology study for suspected arrhythmia
* Investigator decision related to serious comorbidities or identification of reversible cause
* Unable to comply with follow-up procedures
* Previous documented diagnosis of cardiac arrhythmia by holter monitor, event monitor, ECG.
* Currently taking antiarrhythmic medication for a previously documented cardiac arrhythmia
* History of or suspected diagnosis of Postural Orthostatic Tachycardia Syndrome (POTS)
* Patient has unusual thoracic anatomy that precludes proper SEEQ patch placement
* Patient is enrolled in another study that could confound the results of this study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St Elizabeth Healthcare

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas P Carrigan, MD, FHRS

Role: PRINCIPAL_INVESTIGATOR

St Elizabeth Healthcare

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Elizabeth Healthcare

Edgewood, Kentucky, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IMPACT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Medtronic Reveal XT Study
NCT01526343 COMPLETED PHASE2
REVEAL for Respiration Detection
NCT01956578 UNKNOWN NA
Reveal LINQ™ Heart Failure
NCT02758301 COMPLETED
Reveal LINQ Registry
NCT02746471 COMPLETED